Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.

导出 OA

翻译打印收藏纠错

第一作者： Eugene,Shenderov

第一单位： Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu.

作者： Eugene,Shenderov ^[1] ; Angelo M,De Marzo ^[2] ; Tamara L,Lotan ^[3] ; Hao,Wang ^[4] ; Sin,Chan ^[5] ; Su Jin,Lim ^[3] ; Hongkai,Ji ^[4] ; Mohamad E,Allaf ^[5] ; Carolyn,Chapman ^[6] ; Paul A,Moore ^[3] ; Francine,Chen ^[6] ; Kristina,Sorg ^[7] ; Andrew M,White ^[5] ; Sarah E,Church ^[3] ; Briana,Hudson ^[8] ; Paul A,Fields ^[8] ; Shaohui,Hu ^[9] ; Samuel R,Denmeade ^[9] ; Kenneth J,Pienta ^[9] ; Christian P,Pavlovich ^[9] ; Ashley E,Ross ^[10] ; Charles G,Drake ^[11] ; Drew M,Pardoll ^[3] ; Emmanuel S,Antonarakis ^[3]

作者单位： Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu. ^[1] The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu. ^[2] Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. ^[3] Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA. ^[4] Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA. ^[5] Department of Oncology Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, MD, USA. ^[6] Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ^[7] MacroGenics, Inc., Rockville, MD, USA. ^[8] NanoString Technologies Inc., Seattle, WA, USA. ^[9] Adaptive Biotechnologies, Seattle, WA, USA. ^[10] CDI Labs, Baltimore, MD, USA. ^[11] Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ^[12] Immuno-Oncology, Janssen, Horsham, PA, USA. ^[13] The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. ^[14] University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA. ^[15]